2020-07-28T12:46:55-05:00 2019-12-31 EISNERAMPER LLP 733 THIRD AVENUE NEW YORK NY 100172703 990 2019-01-01 364825921 The Mark Foundation for Cancer Research (US) LTD % S PATRICK LEWIS MARK 6468665950 1350 AVENUE OF THE AMERICAS Suite 2 NEW YORK NY 10019 MICHELE CLEARY PHD CEO 6468665950 2020-07-27 true CANDICE METH P01306891 2129498700 64.238.150.4 13478420202105000014 2020-07-28 P 0171DCF37D0058A3A7E131C8AA9958388F37ABDA 0171DCF37D0058A3A7E131C8AA9958388F37ABDA 2019 2020-09-23 17:36:50Z X MICHELE CLEARY PHD 1350 AVENUE OF THE AMERICAS NEW YORK NY 10019 80534924 false X WWW.THEMARKFOUNDATION.ORG X 2015 DE THE MARK FOUNDATION FOR CANCER RESEARCH IS COMMITTED TO ADVANCING BASIC BREAKTHROUGH CANCER RESEARCH, DETECTION, PREVENTION AND CURES FOR CANCER PATIENTS. 4 3 14 0 0 40142140 80000860 0 0 376978 534064 0 0 40519118 80534924 35601108 44049465 0 0 1973152 2221919 0 0 36245 965761 1075545 38540021 47346929 1979097 33187995 33818430 90919630 23857292 47371818 9961138 43547812 X The Foundation actively partners with scientists to accelerate research that will transform the prevention, diagnosis, and treatment of cancer. The Foundation fulfills its mission by supporting groundbreaking science carried out by individual investigators, multi-disciplinary teams, and early-stage companies in the United States and across the globe. Recognizing the obstacles that prevent scientific advances from improving patient outcomes, the Foundation maintains a nimble, high-impact approach to funding basic and translational cancer research that bridges the gap between bench and bedside through grants and venture investments. false false 45663700 44049465 THE FOUNDATION'S grantS reward innovative thinking that advances the understanding of cancer biology and improves oncology treatment paradigms. THE FOUNDATION supports individual investigators, as well as multidisciplinary collaborative teams conducting research across cancer types. THE grantees become part of THE FOUNDATION'S network of the best scientific minds in cancer research and technological innovation. Grant submissions undergo rigorous peer review by the foundations scientific advisory committee or recommended subject matter experts and are held to the strictest standards of scientific excellence. 45663700 true true false false false false false false false false true true false false true true true false false false false true false false false false false true false true false false false false false false false false false false false false false false false false false true 74 0 true 14 true false false false false false false false false false false false false X 4 3 true false false false false false false true false false false true true true true true true true true false NY X S PATRICK LEWIS 6468665950 1350 AVE OF THE AMERICAS SUITE 2902 NEW YORK NY 10019 X MICHELE CLEARY PHD CHAIRMAN OF THE BOARD / CEO 40.0 0.0 X 525820 0 135298 RYAN SCHOENFELD PHD VP, SCIENTIFIC RESEARCH 40.0 0.0 X 304881 0 106170 REBECCA BISH PHD SENIOR SCIENTIFIC DIRECTOR 40.0 0.0 X 236509 0 99427 S PATRICK LEWIS HEAD OF FINANCE AND OPERATIONS 40.0 0.0 X 237861 0 93724 REBECCA LIU SCIENTIFIC PROGRAM OFFICER 40.0 0.0 X 126820 0 41862 KASANDRA DAVIS PROJECT MANAGER 40.0 0.0 X 95500 0 14885 ROSS LEVINE MD PHD DIRECTOR 1.0 0.0 X 10000 0 0 KEVIN O'FLAHERTY DIRECTOR 1.0 0.0 X 0 0 0 WILLIAM ALLEN SHAPARD DIRECTOR 1.0 0.0 X 0 0 0 STUART THOMSON DIRECTOR 1.0 0.0 X 0 0 0 1537391 0 491366 5 false true false ARNOLD PORTER KAYE SCHOLER LLP 601 MASSACHUSETTS AVE NW WASHINGTON DC 200013743 LEGAL SERVICES 116896 1 80000860 80000860 0 534064 534064 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 80534924 534064 42682846 42682846 0 1366619 1366619 0 1463271 959957 490091 13223 0 515597 33950 473316 8331 14110 3860 8152 2098 125859 29509 95833 517 103082 52122 48565 2395 0 146565 85216 58661 2688 87268 87268 0 0 0 79472 9872 69600 0 21385 8627 12482 276 62894 46294 14080 2520 0 316408 70661 242605 3142 110879 107798 3081 0 88119 88119 0 0 49215 20549 27754 912 4766 4766 PAYROLL PROCESSING FEES 17606 8977 8486 143 HONORARIUM 84600 84600 OTHER EXPENSES 6368 4124 2244 47346929 45663700 1646984 36245 772594 1140615 25260696 21299078 0 60000000 0 0 0 0 0 0 0 0 0 0 131911 374316 209798 98649 85263 111149 0 0 7555696 7824375 0 0 0 0 12270 170097 33818430 90919630 420783 438731 23424972 46933087 0 0 0 0 0 0 0 0 0 0 0 0 11537 0 23857292 47371818 X 9961138 43547812 0 0 9961138 43547812 33818430 90919630 X 33187995 268679 130000 X false true X true false X 0 500000 10536000 40142140 80000860 131179000 0 0 0 500000 10536000 40142140 80000860 131179000 57857785 73321215 20684 376978 534064 931726 0 0 132110726 0 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 79445 39758 39687 130353 58891 71462 111149 PRIVATE CO'S PREFERRED STOCKS 7824375 F 7824375 0 0 X 81175803 268679 372200 640879 80534924 80534924 47589129 372200 372200 47216929 130000 130000 47346929 FORM 990, SCHEDULE D, PART X, LINE 2 The Foundation is subject to the provisions of the Financial Accounting Standards Board's (THE "FASB") Accounting Standards Codification ("ASC") Topic 740, Income Taxes, relating to the accounting and reporting for uncertainty in income taxes. Because OF the Foundations GENERAL tax-exempt status, management believes ASC Topic 740 has not had, and is not expected to have, a material impact on the Foundation's financial STATEMENTS. FORM 990, SCHEDULE D, PART XII, LINE 4B PRIOR YEAR GRANTS RETURNED/WITHDRAWN IN THE CURRENT YEAR OF $130,000. true Europe (Including Iceland and Greenland) 0 0 Grantmaking 1118441 North America 0 0 Grantmaking 248178 0 0 0 0 1366619 1366619 Europe (Including Iceland and Greenland) Research 880167 WIRE FMV North America Research 248178 WIRE FMV Europe (Including Iceland and Greenland) Research 238274 WIRE FMV 2 1 false false false false false false FORM 990, SCHEDULE F, PART I, LINE 2 THE FOUNDATION AWARDS RESERACH GRANTS BASED UPON THE GUIDANCE AND INPUT OF THE SCIENTIFIC ADVISORY COMMITTEE AND OTHER HIGHLY REGARDED SCIENTISTS SPECIALIZING IN CANCER RESEARCH. THE FOUNDATION CLOSELY MONITORS THE PROGRESS OF EACH GRANT AWARDED. THERE IS FREQUENT COMMUNICATION BETWEEN GRANTEES AND FOUNDATION STAFF REGARDING THE PROGRESS OF EACH GRANT. IN THE CASE OF MULTI-YEAR GRANTS, PROGRESS IS VERIFIED BEFORE ADDITIONAL GRANTS ARE AWARDED. FORM 990, SCHEDULE F, PART I, LINE 3, COLUMN (F) AMOUNTS REPORTED USING THE ACCRUAL METHOD OF ACCOUNTING. true 4 you and me 2901 3rd Ave Ste 330 Seattle WA 98121 830884908 501(c)(3) 500000 Research Cancer Research Institute 29 Broadway 4th Floor New York NY 10006 131837442 501(c)(3) 750000 Research Carnegie Mellon University 5222 Forbes Avenue Pittsburgh PA 15213 250969449 501(c)(3) 511968 Workshop Support Children's National Medical Center 111 Michigan Ave Washington DC 20010 521640403 501(c)(3) 75000 Research Chordoma Foundation PO Box 2127 Durham NC 27702 208423943 501(c)(3) 500000 Research Cold Springs Harbor Laboratory 1 Bungtown Rd PO BOX 100 Cold Spring Harbor NY 11724 112013303 501(c)(3) 290000 Workshop Support Damon Runyon Cancer Research Foundation One Exchange Plaza 55 Broadway Suite 302 New York NY 10006 131933825 501(c)(3) 897714 Research Dana Farber Cancer Institute Inc 450 Brookline Avenue Boston MA 022150000 042263040 501(c)(3) 5250806 Research Institute For Systems Biology 401 Terry Ave N Seattle WA 981095263 912003593 501(c)(3) 243244 Research Johns Hopkins University 3910 Keswick RD Baltimore MD 21211 520595110 501(c)(3) 2964272 Research Leukemia & Lymphoma Society Inc 3 International Dr Rye Brook NY 10573 135644916 501(c)(3) 1445951 Research Life Sciences Research Foundation 3520 San Martin Dr Baltimore MD 21218 521231801 501(c)(3) 384342 Research Massachusetts General Hospital 55 Fruit Street Boston MA 021140000 042697983 501(c)(3) 722975 Research Massachusetts Institute of Technology 77 Mass Ave Cambridge MA 021390000 042103594 501(c)(3) 961349 Research Memorial Sloan Kettering Cancer Center 1275 York Avenue New York NY 100656007 131924236 501(c)(3) 6356281 Research New York University School of Medicine 550 First Avenue New York NY 10016 135562308 501(c)(3) 722975 Research Oregon Health and Science University 2525 SW 3rd Avenue Suite 245 Portland OR 97201 931176109 501(c)(3) 739119 Research The Jackson Laboratory 600 Main Street Bar Harbor ME 046090000 010211513 501(c)(3) 2758632 Research The Regents of the Univ of CA BerkeLEY 2195 Hearst Avenue Berkeley CA 947201101 946002123 501(c)(3) 1478237 Research The Regents of the Univ of CA Davis One Shields Avenue Davis CA 95616 946036494 501(c)(3) 275912 Research The Regents of Univ of CA San FRANCISCO 1855 Folsom St San Francisco CA 94143 946036493 501(c)(3) 325000 Research The Research Institute at Nationwide Children's Ho 700 Childrens Drive Columbus OH 43205 316056230 501(c)(3) 75000 Research University of Maryland School of Medicine 220 Arch Street Baltimore MD 21201 526002033 501(c)(3) 75000 Research University of Pennsylvania 3451 Walnut St Philadelphia PA 191046284 231352685 501(c)(3) 12011188 Research University of Pittsburgh 116 Atwood Street Pittsburgh PA 15260 250965591 501(c)(3) 1011658 Research University of Texas MD Anderson Cancer Ctr 1515 Holcombe Blvd Houston TX 770307009 746001118 501(c)(3) 692392 Research Weill Medical College of Cornell University 1300 York Avenue New York NY 10065 131623978 501(c)(3) 250000 Research 27 0 FORM 990, SCHEDULE I, PART I, LINE 2 THE FOUNDATION REQUIRES GRANT RECIPIENTS TO COMPLY WITH STATED TERMS AND CONDITIONS GOVERNING EACH RESEARCH PROGRAM AWARDED, INCLUDING THE SUBMISSION OF PROGRESS REPORTS. DISBURSEMENT OF FUNDS IS CONTINGENT UPON ACCEPTANCE OF THESE TERMS AND TIMELY SUBMISSION OF REPORTS. X X X false false false false false false false true false MICHELE CLEARY PHD CHAIRMAN OF THE BOARD / CEO 366820 0 159000 0 0 0 132910 0 2388 0 661118 0 159000 0 S PATRICK LEWIS HEAD OF FINANCE AND OPERATIONS 191095 0 38000 8766 51800 41924 331585 0 38000 RYAN SCHOENFELD PHD VP, SCIENTIFIC RESEARCH 231440 0 64800 8641 83212 22958 411051 0 64800 REBECCA BISH PHD SENIOR SCIENTIFIC DIRECTOR 198509 0 38000 0 57875 41552 335936 0 38000 REBECCA LIU SCIENTIFIC PROGRAM OFFICER 126820 0 0 0 26171 15691 168682 0 0 FORM 990, SCHEDULE J, PART I, LINE 7 STAFF BONUSES ARE AWARDED ON A DISCRETIONARY BASIS UPON THE RECOMMENDATION OF THE CHIEF EXCECUTIVE OFFICER AND APPROVAL BY THE BOARD OF DIRECTORS. FORM 990, SCHEDULE J, PART I, LINE 7 AND PART II, COLUMN B(II) THE CHIEF EXECUTIVE OFFICER IS ENTITLED TO A CONTRACTUAL DISCRETIONARY BONUS AS OUTLINED IN HER EMPLOYMENT AGREEMENT, SUBJECT TO ANNUAL APPROVAL BY THE BOARD OF DIRECTORS PRIOR TO PAYMENT. THIS DISCRETIONARY BONUS IS CONSIDERED A NON-FIXED PAYMENT. FORM 990, PART VI, SECTION A, LINE 2 TWO MEMBERS OF THE BOARD OF DIRECTORS ARE EMPLOYEES OF PAMPLONA CAPITAL MANAGEMENT LLC. ALEX KNASTER (FOUNDER OF THE MARK FOUNDATION FOR CANCER RESEARCH (U.S.) LTD.) IS ALSO THE FOUNDER AND CEO OF PAMPLONA CAPITAL MANAGEMENT LLC. MR. KNASTER DOES NOT HOLD A BOARD SEAT ON THE FOUNDATION'S BOARD. FORM 990, PART VI, SECTION A, LINE 8B GIVEN THE CURRENT SIZE OF THE FOUNDATION'S BOARD OF DIRECTORS, THE FOUNDATION HAS YET TO CREATE COMMITTEES. ALL GOVERNANCE RELATED BUSINESS OF THE FOUNDATION IS CONDUCTED BY THE EXISTING DIRECTORS. FORM 990, PART VI, SECTION B, LINE 11B A COPY OF THE FOUNDATION'S 990 IS PROVIDED TO THE BOARD OF DIRECTORS FOR REVIEW AND COMMENT PRIOR TO ITS ELECTRONIC FILING WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C ALL MEMBERS OF THE BOARD OF DIRECTORS AND KEY MEMBERS OF MANAGEMENT ARE REQUIRED TO REVIEW THE CONFLICTS-OF-INTEREST POLICY AND SIGN IT ON AN ANNUAL BASIS. FORM 990, PART VI, SECTION B, LINES 15A AND 15B THE CHIEF EXECUTIVE OFFICER'S COMPENSATION IS REVIEWED ON AN ANNUAL BASIS BY THE BOARD OF DIRECTORS USING COMPARABLE MARKET DATA. COMPENSATION OF KEY EMPLOYEES IS DETERMINED BY THE CHIEF EXECUTIVE OFFICER AND APPROVED BY THE BOARD OF DIRECTORS ON AN ANNUAL BASIS, AS PART OF THE FOUNDATION'S BUDGET PROCESS. FORM 990, PART VI, SECTION C, LINE 19 THE FOUNDATION'S FORM 990 IS AVAILABLE UPON REQUEST. GOVERNING DOCUMENTS ARE ONLY DISTRIBUTED INTERNALLY TO THE BOARD OF DIRECTORS AND MANAGEMENT. FORM 990, PART VII, SECTION A, LINE 2 ROSS LEVINE MD, PH.D RECEIVED AN HONORARIUM FROM THE FOUNDATION FOR HIS CONTRIBUTIONS TO THE FOUNDATION AS THE CHAIR OF THE FOUNDATION'S SCIENTIFIC ADVISORY COMMITTEE; NOT IN HIS CAPACITY AS A MEMBER OF THE BOARD OF DIRECTORS. FORM 990, PART XI, LINE 9 OTHER CHANGES IN NET ASSETS CONSISTS OF PRIOR YEAR GRANTS RETURNED/WITHDRAWN IN THE CURRENT YEAR OF $130,000.